Table 1.
Nucleoside/tide Reverse Transcriptase Inhibitor (N(t)RTI) a and Phosphorylated Metabolite Concentration. Concentrations are reported as median (min, max).
| TFV (nM) | TFV-dp (nM) | FTC (nM) | FTC-tp (nM) | |
|---|---|---|---|---|
| Plasma (N=14) | 316 (0.44, 1122) b | N/A | 977 (155, 9628) | N/A |
| CVF (N=13) | 394 (4, 7869) c | N/A | 8900 (765, 34021) | N/A |
| Endometrial Tissue (N=3) | 91 (74, 181) | 31 (14, 34) | 1204 (939, 1617) | 161 (115, 163) |
a
The following regimens are represented: TFV/FTC/raltegravir, TFV/FTC/darunavir/ritonavir, TFV/FTC/atazanavir/ritonavir, TFV/FTC/rilpivirine, TFV/FTC/fosamprenavir/ritonavir, and TFV/FTC/elvitegravir/cobicistat.
b
One sample was below the limit of detection (BLD) and reported as 1/2 the lower limit of detection (LLOQ), 0.25ng/ml.
c
Two samples were below the limit of detection (BLD) and reported as 1/2 the lower limit of detection (LLOQ), 2ng/ml.